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Since the time questions arose on cardiovascular safety of Rosiglitazone, FDA has suggested
guidelines on conduct of studies on anti-diabetic drugs so as to prove that the cardiovascular
risk is acceptable. Based on the cardiovascular risks of pre-approval clinical trials, guidelines
have been made to conduct cardiovascular safety outcome trials (CVSOTs) prior to the drug
approval or after the drug has been approved. Unlike the trials comparing the efﬁcacy of
antidiabetic agents, the CVSOTs examine the cardiovascular safety of a drug in comparison to
standard of care. These trials are expensive aspects of drug development and are associated
with various technical and operational challenges. More cost effective models of assessing
cardiovascular safety like use of biomarkers, electronic medical records, pragmatic and
factorial designs can be adopted. This article critically looks at the antidiabetic drug approval
from a cardiovascular perspective by asking a few questions and arriving at answers.
# 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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journal homepage: www.elsevier.com/locate/ihjCardiovascular diseases (CVDs) are the leading cause of death in
subjects with type 2 diabetes.1,2 The primary aim of diabetes
management is to prevent death and morbidity due to CVD and
microvascular diseases. Multifactorial interventions targeting
lifestyle changes, weight loss, lipids, blood pressure, hypergly-
cemia and use of antiplatelet agents have been shown to reduce
the risk of CVD.1,4However, there has been a growing concern on
the adverse cardiovascular outcomes in trials of certain anti-
hyperglycemic agents (AHA) and drug combinations used to* Corresponding author.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).control hyperglycemia.4–6 It would be counterproductive if a
drug used to treat diabetes itself increases the CVD risk.
Following a meta-analysis of randomized controlled trials of
Rosiglitazone, Nissen and Wolski5 concluded that there an
increased risk of myocardial infarction and death in subjects on
Rosiglitazone. This triggered a series of discussion on the need
to more closely evaluate anti-diabetic therapies from a
cardiovascular perspective. In 2008, FDA issued a guidance to
pharmaceutical industry on the conduct of clinical studies tonanag@gmail.com (A. Gopalakrishnan Unnikrishnan),
B.V. This is an open access article under the CC BY-NC-ND license
Table 1 – Salient points of the FDA guidance: Diabetes
mellitus – developing drugs and therapeutic biologicals
for treatment and prevention (from references 7,35).
1. An upper bound of the 95% CI for the risk ratio of important CV
events of 1.3 should be used as a key criterion for excluding
unacceptable CV risk for new treatments of type 2 diabetes.
2. Study patients must include individuals with relatively
advanced disease, elderly patients, and patients with some
degree of renal impairment.
3. A minimum of 2 years' CV safety data must be provided.
4. All phase 2 and phase 3 studies should include a prospective
independent adjudication of CV events. Adjudicated events
should include CV mortality, myocardial infarction (MI), and
stroke and can include hospitalization for acute coronary
syndrome (ACS), urgent revascularization procedures, and
possibly other end points.
5. To satisfy the new statistical guidelines, the analysis of CV
events may include a meta-analysis of all placebo controlled
trials, add-on trials (i.e., drug vs. placebo, each added to standard
therapy), and active-controlled trials, and/or an additional single,
large safety trial may be conducted that alone, or added to other
trials, would be able to satisfy this upper bound before a new
drug application/biologics license application (NDA/BLA) is
approved.
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safety.7 In this article, we try to answer the anti-diabetic drug
approval process from a cardiovascular perspective. The
authors selected few signiﬁcant questions, which needed to
be answered. A PubMed search was done with terms diabetes
and cardiovascular outcome and cardiovascular trials. All
article abstracts were screened, and articles answering our
questions were selected.
1. What was the traditional FDA speciﬁcations
for anti-diabetic drug approval?
Prior to the guidance, the process of drug approval required the
sponsors to submit the phase 2 and phase 3 trial data on at
least 2500 subjects exposed to the investigational product. At
least 1300–1500 of these subjects should be exposed to the
investigational product for >1 year and at least 300–500
subjects exposed to the investigational product for >18
months.8 The end point of efﬁcacy was glycosylated hemo-
globin (HbA1c).7 As per guidelines, these trials used the
investigational agent as monotherapy or as an add on therapy.
The cardiovascular adverse effects of these therapies were
made out from the cardiovascular events that would occur
during the course of the trial. These cardiovascular events
were not pre-speciﬁed and not centrally independently
adjudicated. Since the subjects included in these trials were
younger, of low CV risk (patients with CV events usually
excluded), shorter duration of disease and in shorter trial
duration, the number of CV events accrued during the course
of the trial would be low. The low event rates and lack of
independent adjudication lead to poor estimates of CV safety
of these agents.
2. What were the salient points in the FDA
guidance issued in 2008?
The guidance issued by FDA in 2008 recommended that a new
anti-diabetic drug should not increase cardiovascular risk to
an unacceptable extent.7 The key recommendations are
summarized in Table 1.
The FDA also deﬁned the point estimates and upper limit of
95% conﬁdential intervals of risk ratios (1.3 and 1.8) for
cardiovascular events in comparison to control group, which
should prompt industry to design a post marketing or pre-
marketing cardiovascular outcome trials (CVOTs).7,8CVOT since
then have become an integral part of the drug approval process
of anti-diabetic therapies. CVOT, despite its simplicity in design
is often misunderstood as trials of glycemic efﬁcacy by both
practitioners and experts.9 With CVOT like Saxagliptin Assess-
ment of Vascular Outcomes Recorded in Patients with Diabetes
Mellitus (SAVOR-TIMI 53), Trial to Evaluate Cardiovascular
Outcomes after Treatment with Sitagliptin (TECOS), Examina-
tion of cardiovascular outcomes with alogliptin (EXAMINE),
Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA)
and EMPA-REG OUTCOME already completed and with more
trials to follow, it is important that all stake holders including
clinicians in diabetes and cardiovascular practice know the key
features of these trials.10–133. How are regulatory CVOT different from
trials like UKPDS, PROactive, ACCORD, ADVANCE
and VADT?
Any trial reporting a single or composite of cardiovascular end
points is labeled as a CVOT. Holman et al. analyzed trials with
>1000 subjects and >1 year duration for his analysis of CVOT.14
These can be of various types
(A) Trials reporting cardiovascular outcomes according to
treatment goals (e.g. Action to Control Cardiovascular Risk
in Diabetes (ACCORD), Veterans Affairs Diabetes Trial
(VADT), Hyperglycemia and its Effect After Acute Myocar-
dial Infarction on Cardiovascular Outcomes in Patients
with Type 2 Diabetes Mellitus (HEART2D)).15,16
(B) Trials reporting CV outcomes as a part of other total
outcomes (e.g. UKPDS, DCCT). They may test 2 treatment
goals with different regimes.17,18
(C) Trials looking at HbA1c goals and speciﬁc drugs and/or
strategies e.g. Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled Evaluation (AD-
VANCE), Bypass Angioplasty Revascularization Investiga-
tion 2 Diabetes (BARI 2D) trial.19
(D) Trials comparing CV outcomes of 2 different agents e.g.
Cardiovascular Outcome Study of Linagliptin versus
Glimepiride in Patients with Type 2 Diabetes (CAROLINA),
A Trial Comparing Cardiovascular Safety of Insulin
Degludec Versus Insulin Glargine in Subjects With Type
2 Diabetes at High Risk of Cardiovascular Events (DEVOTE)
and Thiazolidinediones or Sulfonylureas and Cardiovas-
cular Accidents Intervention Trial (TOSCA.IT).20,21
(E) Trials looking at cardiovascular safety/beneﬁts of speciﬁc
drugs (e.g. SAVOR-TIMI 53, TECOS, EXAMINE, ELIXA,
Liraglutide Effect and Action in Diabetes: (LEADER), EMPA
REG OUTCOME, Canagliﬂozin cardiovascular assessment
Study (CANVAS), Trial to Evaluate Cardiovascular and
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With Type 2 Diabetes (SUSTAIN), Effect of Dapagliﬂozin on
the Incidence of Cardiovascular Events (DECLARE TIMI 58),
Cardiovascular and Renal Microvascular Outcome Study
With Linagliptin in Patients With Type 2 Diabetes Mellitus
(CARMELINA), Ertugliﬂozin CVOT).10,11,22,23
Although broadly divided into 5 groups, there is some
overlap in this classiﬁcation. The last 2 groups (D and E) of
CVOT trial design is used for satisfying the current FDA
requirement of acceptable safety of AHA. In fact they could be
appropriately called ‘‘CV safety outcome trials (CVSOT)’’ to
differentiate it from other trials reporting CV outcomes.24
DEVOTE trial stands out as the only regulatory trial of insulin,
where Degludec is compared to Glargine.14
Often the UKPDS is quoted to highlight the favorable
cardiovascular beneﬁts of Metformin in obese subjects with
type 2 diabetes. The UKPDS study recruited subjects with type 2
diabetes at diagnosis with low cardiovascular risk. In UKPDS
glucose control study, the prevalence of CV risk factors were
low: 0.3% of subjects were on lipid lowering therapy, 1.6% on
antiplatelet therapy, 12% on antihypertensive medication,
around 2% had proteinuria and 34% were current smokers.17
The standard of care for CV risk factors in 1977, when the study
started were different from the ones we use now. Subjects with
history of myocardial infarction within 1 year or with heart
failure were excluded.17 This is evident with the low event rates
in the trial despite lack of CV protective therapies.17 Of the 4209
randomized subjects in UKPDS, only 342 subjects were in
Metformin arm. This is miniscule by current CVSOT stan-
dards.25 Even though a 10-year follow-up of the trial showed a
favorable CV outcome, the lack of event adjudication, changing
standard of care over the course of the trial, small number of
patients on follow-up, non-trial format follow-up and follow-up
losses would rate the outcomes inferior to current format of
CVSOT.26 The Glucose Lowering In Non-diabetic hyperglycemia
Trial (GLINT) will examine the effects of Metformin on
cardiovascular outcomes in subjects with high CV risk and
non-diabetes dysglycemia.27
The ACCORD, VADT, and ADVANCE were trials testing
different targets of glycemic control rather than strate-
gies.15,16,19 ACCORD reported cardiovascular outcomes in
groups of subjects randomized to achieve HbA1c <6% vs. a
target of 7.0–7.9% in subjects with high CV risk.15 In ADVANCE,
the therapeutic strategy involved Diamicron MR (sustained
release gliclazide preparation) to target an HbA1c <6.5% vs.
standard care in subjects at high CV risk.19 In ADVANCE,
subjects, who were the control arm, were not treated to equal
glycemic targets and drugs with potential similar mechanisms
(i.e. Sulphonylureas) were used in the control arm.19 In VADT,
subjects with high CV risk were randomized to receive
treatment with AHA to achieve stricter HbA1c targets in the
intensive treatment arm (1.5% less than standard group) and
outcomes were compared at the end of the trial.16
The PROactive and Rosiglitazone Evaluated for Cardiovas-
cular Outcomes and Regulation of Glycaemia in Diabetes
(RECORD) trials did look at CV outcomes with Pioglitazone
and Rosiglitazone respectively.28 PROactive included subjects
with prior CV events and attempted to achieve glycemic
equipoise in both the arms. Outcome events were adjudicatedindependently.28 The RECORD trial did include some subjects
with CVD and followed a policy to titrate glycemic therapy to
achieve a target HbA1c. Cardiovascular events were adjudicat-
ed. However the low event rates and high drop out in the trial
limited the conclusions.29
4. How does a regulatory Cardiovascular
Safety Outcome Trials (CVSOT) differ from trials of
glycemic efﬁcacy?
In trials of glycemic efﬁcacy, subjects with diabetes with a
certain degree of glycemic control (as deﬁned by HbA1c),
baseline drugs, age, and BMI criteria are randomized to receive
an investigational drug or a comparator/placebo. The subjects
are followed up for a period of time to assess the drug efﬁcacy
in reducing parameters of glycaemia (e.g. Fasting Plasma
Glucose, Postprandial plasma glucose or HbA1c). The other
parameters, which were commonly compared included
hypoglycemia risk, weight gain, blood pressure, lipid proﬁle
and measures of beta cell function and insulin sensitivity.30
In contrast, CVSOT are trials designed to ﬁnd out how a drug
performs in comparison to standard care in terms of pre-deﬁned
cardiovascular end points. These studies randomize patients
with diabetes and high cardiovascular event rates so as to
accrue the required number of CV events in the limited time
periods of the trial. In CVSOT, subjects with high cardiovascular
risk or preexisting atherosclerotic vascular disease are random-
ized to 2 arms: one arm receives a standard of care and the other
arm receives the investigational drug in addition to the standard
of care. Investigators are blinded to the therapies and are
allowed to titrate glycemic therapies in both the arms similarly
except that the tested drug (or a drug, which acts by a similar
mechanism) not be added during the course of trial. These trials
are event driven i.e., the trial stops, when a certain number of
events accumulate in the trial. It is expected that the glycemic
control in both the arms of the trial are similar (glycemic
equipoise) since it is left to the investigator to adjust the
glycemic therapy in both the arms.12 (Fig. 1). CVSOT differs from
trials of glycemic efﬁcacy in a number of ways (Table 2).
These CVSOT deﬁne their outcomes as a combination of
Major Adverse Cardiovascular Events (MACE). These are
nonfatal myocardial infarction, nonfatal stroke and cardiovas-
cular death. Other major cardiovascular events of interest are
hospitalization for angina, hospitalization for heart failure,
urgent revascularization for unstable angina and death from
any cause. Most CVOT use a composite of MACE with or without
other CV endpoints of interest as their primary outcome. E.g.
SAVOR-TIMI 53, EMPA-REG OUTCOME and EXAMINE used a
primary endpoint of composite MACE, TECOS used a composite
of MACE and hospitalization for unstable angina as the primary
outcome. Secondary outcomes may be a combination or
individual components of these cardiovascular end points.10–13
5. Do CVSOT reﬂect the true CV beneﬁts of
drugs?
The follow-up of UKPDS has shown the beneﬁts of early
intensive glycemic control on CV events in newly diagnosed
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Fig. 1 – Conduct of a cardiovascular outcome trial. # High CV risk features may be predefined in the trial (e.g. age >50 years,
dyslipidemia, hypertension, albuminuria, smoking etc.) and CV events (previous ACS, CABG, previous PCI, carotid stenosis,
peripheral vascular disease, heart failure). * The primary end point is a composite of first occurrence of non-fatal MI, non-fatal
stroke or CV death. The secondary endpoints may be a hospitalization for ACS, urgent revascularization, heart failure, all-
cause mortality or a combination of these.
Table 2 – Comparison of trials of glycemic efficacy and CVSOTs.
Glycemic efﬁcacy trial CVSOT
Objective Efﬁcacy of drug compared to placebo or comparator Compare CV outcomes
Number of patients 300–600 (based on sample size calculation) In thousands
Duration 26–104 weeks Many years or event driven
Back ground glycemic
therapies titration
Limited to rescue therapies and dose
changes for hypoglycemia
More ﬂexibility for investigator
Comparator Placebo or active comparator Usually placebo (exceptions are CAROLINA, DEVOTE and
TOSCA.IT)
Inclusion/Exclusion Mainly low risk patients or minimal CV risk High CV risk factors (SAVOR TIMI 53), known
atherosclerotic vascular disease (SAVOR TIMI 53, TECOS,
EMPA REG OUTCOME), recent CV event (EXAMINE, ELIXA)
Primary outcomes HbA1c and or FPG reduction Composite of major adverse cardiovascular events (MACE)
CAROLINA: Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes. DEVOTE: A Trial Comparing
Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Subjects with Type 2 Diabetes at High Risk of Cardiovascular Events.
TOSCA.IT Thiazolidinediones or Sulfonylureas and Cardiovascular Accidents Intervention Trial.
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the beneﬁts of multifactorial intervention controlling glycae-
mia, lipids and blood pressure to strict targets in reducing both
microvascular and macrovascular disease.3 This gives the
evidence for better control of risk factors on incidence of CV
disease in type 2 diabetes. The beneﬁcial effect of AHA on the
CV system is a function of improved glycemic control, effects
on known CV risk factors (e.g. lipids, weight, and blood
pressure) and other currently ‘‘unknown factors’’. Taking out
the effects of improved glycemic control by attaining glycemic
equipoise in both the arms of the CVOT and achieving a high
percentage of statin use, antiplatelet use and Renin–Angio-
tensin–Aldosterone system inhibitors in both the arms leaves
only the ‘‘unknown ‘‘factors to play out in deciding the CV
effects of the AHA. The subjects in these trials are older, having
diabetes of longer duration and established CV disease or risk
factors. This makes retarding progress of atherosclerotic
process a rare possibility within the period of study. However
these trials may demonstrate potential for harm (inferiority),lack of adverse CV outcome (non-inferiority) or cardiovascular
beneﬁts (superiority) by mechanisms other than interference
with the atherosclerotic process.
The EMPA-REG OUTCOME, the CVOT of empagliﬂozin
showed signiﬁcant improvements in composite primary
outcome (MACE), death from cardiovascular causes, hospital-
ization from heart failure and all-cause mortality. The possible
mechanisms underlying these improvements are likely to be
‘‘multidimensional’’ and ‘‘speculative’’ as per the authors.13
The time course of primary outcome event reduction favors an
effect of Empagliﬂozin on the volume status of the subjects.31
6. What important information can be got from
CVSOT?
Most CVSOT are designed to prove non-inferiority and later
superiority if the non-inferiority criteria are met.10,13,23 These
trials establish the cardiovascular safety of investigational
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CV events. Since these events are pre-speciﬁed and centrally
adjudicated, there is uniformity of reporting and event capture
across multiple sites across geographical areas. This is a major
step compared to the pre-guidance era, where the CV events
were pre-speciﬁed and recorded as serious adverse events but
not centrally adjudicated. Central adjudication of end points
has been found to improve reporting of events in some studies
but not all.32,33 This may apply even to hard end points like
acute myocardial infarction.32 Pooling of data from phase
2/phase 3 trials, especially if they are not adjudicated centrally
may give an entirely different picture from a CVOT as seen
with Saxagliptin.10,34
To capture the number of CV events to attain non-
inferiority, large number of trial subjects are required. Even
larger number of subjects are needed if the drug is trying to
prove superiority.35,36 The sheer number of subjects studied in
these trials gives an opportunity to study rare adverse effects
of these drugs. Beyond the CV outcomes, trials like TECOS,
SAVOR-TIMI 53 and EXAMINE gave valuable insights into risk
of pancreatitis, pancreatic cancer, renal outcomes, fracture
risk and risk of various malignancies in the study popula-
tion.11,12 These outcomes of interest are pre speciﬁed and
centrally adjudicated. Further study of exploratory end points
in certain trials e.g. calcitonin levels (LEADER), NT-pro BNP
(SAVOR-TIMI 53) and fractures (CANVAS) could give some
mechanistic insight into complications that are of inter-
est.10,22,23 From CVSOT we have come to realize that individual
molecules may have off target actions, which may be different
from actions speciﬁc to the class of molecules. E.g. increased
risk of heart failure due to hospitalization was shown SAVOR-
TIMI 53, but not in EXAMINE or TECOS.10,12
Certain adverse effects may emerge only after signiﬁcant
patient years of exposure. This is possible with large patient
numbers in CVSOT. The CVOT of dual PPAR ag agonist,
Aleglitazaar (AleCardio) involved high risk subjects with recent
acute coronary event as the study population. The trial was
stopped prematurely by the data monitoring committee due to
safety issues associated with heart failure, gastrointestinal
bleeds and weight gain, which was felt to outweigh the
expected CV beneﬁts the drug.37 Many of these serious adverse
effects of Aleglitazaar were not seen in pooled trials of shorter
duration.38 Casting a wider net of inclusion criteria to include
elderly individuals, individuals with various stages of CKD and
hepatic dysfunction, older women and multiethnic subjects
would help identify more potential adverse outcomes.
7. What are the possible limitations in
information gathered in CVSOT?
As alluded earlier, the true CV beneﬁts of the drug (which is the
function of glycemic lowering and effect on known risk factors)
a may not be derived from CVSOT. The possible beneﬁcial
results of CVSOT cannot be applied to a population, where it
has not been studied. E.g. the CV mortality reduction with
subjects on empagliﬂozin in the EMPA-REG OUTCOME trial
cannot possibly applied to a younger group of type 2 diabetes
subjects with low CV risk.13 However, this could be the
population, where the drug is probably going to be used more.Since CVSOT have strict entry criteria, they may not have a
population similar to the spectrum of subjects in the
community that would use the drug. Hence some adverse
effects may surface only during the post marketing surveil-
lance e.g. euglycemic diabetic ketoacidosis related to SGLT-2
inhibitors were identiﬁed in the post marketing program
rather than in large CVSOT.39 CVSOT includes comparison of
an investigational agent to standard care. However, standard
of care may consist of therapies and combination of therapies
with unproven CV track records.35 This may include agents
like SU and Pioglitazone, which may have their own baggage of
potential CV adverse effects. The potential of slight excess
of these therapies in the arms may confound the results of
these trials, which may not be measurable.40
A composite outcome is made up of 2 or more component
outcomes. Any patient, who experiences any one of the
outcomes is considered to have experienced the composite
outcome. Using composite outcomes increases statistical
efﬁciency because of higher event rates, reduces sample size,
costs and time.41 Chosen carefully, composite outcomes will
reﬂect a sum total of meaningful endpoints of interest, which
may have a common pathophysiology or clinical implication.
In CVSOT, the recommended primary outcome is a composite
outcome of CV death, non-fatal MI and non-fatal ischemic
stroke.13,42 However, the treatment effect sizes may vary
between the components of the composite outcome e.g. in
EMPA-REG OUTCOME, the risk of cardiovascular death 0.62
(95% CI: 0.49–0.77) inﬂuenced the primary composite outcome
(HR: 0.86 (95% CI: 0.74–0.99)) much more than the other 2
components: risk of non-fatal MI 0.87 (95% CI: 0.70–1.09) and
non-fatal stroke 1.24 (95% CI: 0.92–1.67).13 Unless speciﬁcally
explained, it is likely that readers will consider that the drug
had similar effects on each of the individual outcomes.
Further, for certain ﬁndings of a trial, a potential mecha-
nistic explanation may not be available and it may even
conﬂict the current knowledge on the subject. E.g. the
increased risk of heart failure in the Saxagliptin arm of
SAVOR-TIMI despite a positive effect of GLP-1 on heart failure
in animal models.43 Rapid reduction of CV mortality starting
within the ﬁrst year in subjects using empagliﬂozin in the
EMPAREG OUTCOME trial, which conﬂicts with the known
potential glycemic beneﬁts and the known potential CV risk
beneﬁts of the drug.13 However, these would be an impetus to
undertake smaller mechanistic studies to explore the ﬁndings
of the trial.
8. What are the operational and technical
challenges with CVSOT?
The cost of successfully bringing a drug to the market is tagged
at 1.5 billion USD.44 The true cost of drug development
including late stage failures are 4–5 billion USD and may go up
to 12 billion USD.44 CVSOT are expensive aspects of drug
development program and are likely to escalate the costs,
which are passed to the end-consumer. These trials involve
large number of subjects, investigators and sites across
different countries. This would involve challenges in lab
shipments, IVRS based randomization, different cost struc-
tures, temperature controlled transport of drugs, customs
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variable ethics committee practices.45 This may lead to
sponsors selectively choosing ‘‘trial friendly’’ countries and
those countries, where regulatory requirements necessitate
enrolling local population before approval of drug. There
would be challenges in adhering to local regulatory practices
and local practices of ‘‘standard of care’’. Since these trials are of
long duration, there will be challenges in patient retention,
changes in investigator and stafﬁng of trial sites and interpre-
tation of missing data.14,45 Ethnic variations may be present in
efﬁcacy and adverse effects to a drug in addition to challenges in
weight based dosing (e.g. Asian patients may have lower body
weight but may use the same dose as Caucasian population).
There are challenges further in doing CV safety trials with
insulin.46 Unlike other new AHA getting approved for diabetes,
insulin is associated with hypoglycemia. Undertaking CVSOT
with insulin will run challenges of increased risk of hypoglyce-
mia, need to have treat-to-target models to ensure glycemic
equipoise and challenges of blinding when using 2 different
types of insulin. Further, there is an increased risk of CV events
in subjects with severe hypoglycemia, which should be factored
into the trial analysis.15
Event rate for primary endpoints is one of the factors, which
determine sample size of a trial. Low observed event rate
during the course of the trial may lead to increased recruit-
ment of high-risk patients and these may adversely reﬂect on
outcome of trials.42 One of the challenges would be to design
trials to satisfy needs for different regulatory agencies. EMA
requires sponsor to have phase 2/3 studies, which may last up
to 18–24 months and include sufﬁcient subjects with high CV
risk, renal dysfunction and elderly. These data would be
expected to be entered into a meta-analysis. The need for
CVSOT will be decided if there is an adverse CV signal or
unacceptable lack of precision.47 FDA has speciﬁed more
deﬁnite criteria for conduct of CVSOT.7 The Japanese Phar-
maceuticals and Medicines Development Agency does not
require CVSOT for drug approval of AHA.45
Further, these ﬁnancial resources could otherwise be used
for more potential health research priorities. CVSOT in the
current format would only help to identify a segment of
subjects, where the drug has potential to be used safely. This
would automatically be extrapolated to be safety in a
population with low risk although the converse may not be
true with regards to potential beneﬁt. There is a concern that
CVSOT, when conducted in a community will tend to recruit a
large number of subjects. This would potentially limit the
number of subjects could enter other drug developmental
programs.
9. Can there be any improvements in conduct
of CVSOT?
With some limitations, CVSOT can be considered a gold
standard to establish the CV safety of AHA. There has been an
outcry from both professionals and patient groups on
escalating costs of antidiabetic drug development, where
CVSOT are involved potentially draining resources, delaying
drug development and approval.14,24,44,48,49 With a thought
toward minimizing the cost of drug development withoutcompromising patient safety, alternatives methods may need
to be considered.
Using a larger bouquet of CV outcomes in addition to 3 point
MACE (CV mortality, MI, and stroke) as primary composite end
point would be one of these. This can include new onset
angina, evidence of reversible ischemia, hospitalization for
acute coronary syndrome, urgent revascularization proce-
dures, heart failure hospitalizations, ECHO proven Regional
Wall Motion Abnormalities, Left Ventricular End Diastolic
Volume, asymptomatic carotid artery stenosis and peripheral
vascular disease. However, increasing components of com-
posite outcome may increase event rates leading to shorter
trial duration, but reduce precision of study and mask
treatment effects.50 This would also run a risk of under-
estimating the possible beneﬁts of drug in reducing certain
related outcomes.
Phase 2 and Phase 3 trials of antidiabetic drugs should
include the use of CV biomarkers and in addition to hard end
points. This can include but not limited to more established
biomarkers such as QT intervals, heart rate, hsCRP, carotid-
intima media thickness, lipids, and body weight. Newer
biomarkers in the horizon such as ﬁbrinogen, amyloid A,
Pentraxin 3, homocysteine, and soluble CD40 ligand can also
be considered.51 These trials should also look out for signs with
potential association with CV risk like ECG abnormalities,
edema, heart rate changes, weight gain, unfavorable lipid and
blood pressure changes. Although individual parameters by
themselves may not be decisive, combinations of biomarkers
and clinical parameters may show trend toward beneﬁt or
harm. A conceptual developmental framework for CV safety
assessment at various stages of drug development has been
proposed.24 However, previous trials have shown that, where
the disease process is multifactorial, favorable surrogate
markers may not always translate into positive hard out-
comes.37,52,53
High-risk subjects are chosen in CVSOT since their CV event
rates are higher. But in a background of cardio protective
therapies (statins, antiplatelet and antihypertensive), the
event rates are still low necessitating larger patient popula-
tion. If we were to identify patient characteristics (clinically,
genomics or by metabolomics), more targeted therapy could be
studied (precision medicine) in larger number of subjects in
early phase studies.44 This could potentially reduce the need
for CVSOT and late stage drug failures.44
Current format of CVSOT would achieve the aim of
excluding cardiovascular toxicity during the course of study
that would last few years. However, longer follow-up of these
subjects would help understand off-target effects of the drug
and its adverse effects including carcinogenicity. This may be
resource intensive and may require a regulatory–sponsor
ﬁnancial and technical collaboration.
Since clinical trials are conducted outside the routine
clinical care system, they involve extra staff, investigators and
documentation, which contributes to massive cost. In an era of
electronic health records, it would be possible to integrate
clinical trial participation with routine clinical care. Electronic
records would help subject identiﬁcation for participation in
trials, capture baseline data without duplication, identify
concomitant medications and help follow events of interest.14
Various alternatives for CVSOT based on large observational
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 5 6 4 – 5 7 1570data, electronic health records and Big Data’’ has been
proposed by the Cardiac Safety Research Consortium.24
Various alternative trial designs like ‘‘factorial design ‘‘and
‘‘pragmatic design’’ has been proposed for CVSOT.8 Establish-
ment of a strong pharmacovigilance program could help
identify potential risk with AHA. Diabetes being a very
prevalent disease, the number of subjects exposed to a newly
introduced AHA within a short time would be potentially large.
An integrated pharmacovigilance system based on electronic
records and spread across different geographic areas, where
the drug will help generate useful safety and efﬁcacy data.
10. Conclusion
CVSOT can be considered as a gold standard for establishing
the cardiovascular safety of anti-diabetic agents. These trials
are not done to evaluate the glycemic efﬁcacy of a drug but to
understand if the drug increases the risk for cardiovascular
outcomes. These trials are multicentric and involve signiﬁcant
logistic and operational challenges. However they serve to give
valuable information beyond CV safety. A more cost effective
approach to cardiovascular safety assessment of these agents
balancing both costs and beneﬁts would be the ideal way
forward.
Conﬂicts of interest
The authors have none to declare.
Authors contribution
Mathew John (MJ), Ambika Gopalakrishnan Unnikrishnan
(AGU), Sanjay Kalra (SK), Tiny Nair (TN).
Concept: MJ, AGU, SK.
Design: MJ, SK, TN.
Literature search: MJ, AGU, SK, TN.
Analysis of literature: MJ, AGU, SK, TN.
Initial preparation of manuscript: MJ, SK.
Editing: TN, SK.
Review of manuscript: MJ, AGU, SK, TN.
Final approval of manuscript: MJ, AGU, SK, TN.
All the authors, whose names are mentioned have
contributed signiﬁcantly to merit authorship of the manu-
script. All the authors have read and approved the ﬁnal copy of
the manuscript.
r e f e r e n c e s
1. Fox CS, Golden SH, Anderson C, et al. Update on
prevention of cardiovascular disease in adults with type 2
diabetes mellitus in light of recent evidence: a scientiﬁc
statement from the American Heart Association and
the American Diabetes Association. Diabetes Care.
2015;38:1777–1803.
2. Go AS, Mozaffarian D, Roger VL, et al. Executive summary:
heart disease and stroke statistics – 2013 update: a reportfrom the American Heart Association. Circulation.
2013;127:143–152.
3. Gaede P, Lund-Andersen H, Parving H-H, et al. Effect of a
multifactorial intervention on mortality in type 2 diabetes. N
Engl J Med. 2008;358:580–591.
4. Rao AD, Kuhadiya N, Reynolds K, et al. Is the combination of
sulfonylureas and metformin associated with an increased
risk of cardiovascular disease or all-cause mortality?: a
meta-analysis of observational studies. Diabetes Care.
2008;31:1672–1678.
5. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of
myocardial infarction and death from cardiovascular
causes. N Engl J Med. 2007;356:2457–2471.
6. Salsburg DS. The UGDP study. JAMA. 1971;218:1704–1705.
7. US Food and Drug Administration Guidance for industry:
Diabetes mellitus — Evaluating cardiovascular risk in new
antidiabetic therapies to treat type 2 diabetes [Internet]. [cited
2015 Nov 22]; Available from: http://www.fda.gov/downloads/
drugs/guidancecomplianceregulatoryinformation/guidances/
ucm071627.pdf.
8. Bethel MA, Sourij H. Impact of FDA guidance for developing
diabetes drugs on trial design: from policy to practice. Curr
Cardiol Rep. 2012;14:59–69.
9. Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of
diabetes drugs – insights from the rosiglitazone experience.
N Engl J Med. 2013;369:1285–1287.
10. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and
cardiovascular outcomes in patients with type 2 diabetes
mellitus. N Engl J Med. 2013;369:1317–1326.
11. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute
coronary syndrome in patients with type 2 diabetes. N Engl J
Med. 2013;369:1327–1335.
12. Green JB, Bethel MA, Armstrong PW, et al. Effect of
sitagliptin on cardiovascular outcomes in type 2 diabetes. N
Engl J Med. 2015;373:232–242.
13. Zinman B, Wanner C, Lachin JM, et al. Empagliﬂozin
cardiovascular outcomes, and mortality in type 2 diabetes. N
Engl J Med. 2015;373:2117–2128.
14. Holman RR, Sourij H, Califf RM. Cardiovascular outcome
trials of glucose-lowering drugs or strategies in type 2
diabetes. Lancet Lond Engl. 2014;383:2008–2017.
15. Action to Control Cardiovascular Risk in Diabetes Study
Group. Gerstein HC, Miller ME, et al. Effects of intensive
glucose lowering in type 2 diabetes. N Engl J Med.
2008;358:2545–2559.
16. Duckworth W, Abraira C, Moritz T, et al. Glucose control and
vascular complications in veterans with type 2 diabetes. N
Engl J Med. 2009;360:129–139.
17. UK Prospective Diabetes Study (UKPDS) Group. Intensive
blood-glucose control with sulphonylureas or insulin
compared with conventional treatment and risk of
complications in patients with type 2 diabetes (UKPDS 33).
Lancet Lond Engl. 1998;352:837–853.
18. The Diabetes Control and Complications Trial Research
Group. The effect of intensive treatment of diabetes on the
development and progression of long-term complications in
insulin-dependent diabetes mellitus. N Engl J Med.
1993;329:977–986.
19. ADVANCE Collaborative Group. Patel A, MacMahon S, et al.
Intensive blood glucose control and vascular outcomes
in patients with type 2 diabetes. N Engl J Med. 2008;358:
2560–2572.
20. Marx N, Rosenstock J, Kahn SE, et al. Design and baseline
characteristics of the CARdiovascular Outcome Trial of
LINAgliptin Versus Glimepiride in Type 2 Diabetes
(CAROLINA®). Diabetes Vasc Dis Res. 2015;12:164–174.
21. Vaccaro O, Masulli M, Bonora E, et al. The TOSCA.IT trial: a
study designed to evaluate the effect of pioglitazone versus
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 5 6 4 – 5 7 1 571sulfonylureas on cardiovascular disease in type 2 diabetes.
Diabetes Care. 2012;35:e82.
22. Marso SP, Poulter NR, Nissen SE, et al. Design of the
liraglutide effect and action in diabetes: evaluation of
cardiovascular outcome results (LEADER) trial. Am Heart J.
2013;166:823–830. e5.
23. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and
baseline characteristics of the Canagliﬂozin Cardiovascular
Assessment Study (CANVAS) – a randomized placebo-
controlled trial. Am Heart J. 2013;166:217–223. e11.
24. Sager PT, Seltzer J, Turner JR, et al. Cardiovascular Safety
Outcome Trials: a meeting report from the Cardiac Safety
Research Consortium. Am Heart J. 2015;169:486–495.
25. UK Prospective Diabetes Study (UKPDS) Group. Effect of
intensive blood-glucose control with metformin on
complications in overweight patients with type 2 diabetes
(UKPDS 34). Lancet Lond Engl. 1998;352:854–865.
26. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of
intensive glucose control in type 2 diabetes. N Engl J Med.
2008;359:1577–1589.
27. The Glucose Lowering In Non-diabetic hyperglycaemia Trial
(GLINT) – Glucose lowering in those at risk of diabetes
[Internet]. ISRCTN Registry. [cited 2015 Nov 22]; Available
from: http://www.isrctn.com/ISRCTN34875079
28. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary
prevention of macrovascular events in patients with type 2
diabetes in the PROactive Study (PROspective pioglitAzone
Clinical Trial In macroVascular Events): a randomised
controlled trial. Lancet. 2005;366:1279–1289.
29. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone
evaluated for cardiovascular outcomes – an interim
analysis. N Engl J Med. 2007;357:28–38.
30. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the
dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy
on glycemic control in patients with type 2 diabetes. Diabetes
Care. 2006;29:2632–2637.
31. DeFronzo R, McMurray J. EMPA-REG – the diuretic hypothesis.
J Diabetes Complicat. 2015. http://dx.doi.org/10.1016/j.jdiacomp.
2015.10.012.
32. Mahaffey KW, Harrington RA, Akkerhuis M, et al. Systematic
adjudication of myocardial infarction end-points in an
international clinical trial. Curr Control Trials Cardiovasc Med.
2001;2:180–186.
33. Granger CB, Vogel V, Cummings SR, et al. Do we need to
adjudicate major clinical events? Clin Trials. 2008;5:56–60.
34. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic
assessment of cardiovascular outcomes in the saxagliptin
drug development program for type 2 diabetes. Postgrad Med.
2010;122:16–27.
35. Hirshberg B, Raz I. Impact of the U.S. Food and Drug
Administration cardiovascular assessment requirements on
the development of novel antidiabetes drugs. Diabetes Care.
2011;34:S101–S106.
36. Menon V, Lincoff AM. Cardiovascular safety evaluation in
the development of new drugs for diabetes mellitus.
Circulation. 2014;129:2705–2713.
37. Lincoff AM, Tardif JC, Schwartz GG, et al. Effect of aleglitazar
on cardiovascular outcomes after acute coronary syndromein patients with type 2 diabetes mellitus: the AleCardio
randomized clinical trial. JAMA. 2014;311:1515–1525.
38. Henry RR, Buse JB, Wu H, et al. Efﬁcacy, safety and
tolerability of aleglitazar in patients with type 2 diabetes:
pooled ﬁndings from three randomized phase III trials.
Diabetes Obes Metab. 2015;17:560–565.
39. US Food and Drug Administration FDA Drug Safety
Communication: FDA warns that SGLT2 inhibitors for
diabetes may result in a serious condition of too much acid
in the blood [Internet]. [cited 2015 Nov 21]; Available from:
http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm.
40. Zhong J, Goud A, Rajagopalan S. Glycemia lowering
and risk for heart failure: recent evidence from studies
of dipeptidyl peptidase inhibition. Circ Heart Fail. 2015;8:
819–825.
41. Cordoba G, Schwartz L, Woloshin S, et al. Deﬁnition,
reporting, and interpretation of composite outcomes in
clinical trials: systematic review. BMJ. 2010;341:c3920.
42. Scirica BM, Bhatt DL, Braunwald E, et al. The design and
rationale of the saxagliptin assessment of vascular
outcomes recorded in patients with diabetes mellitus-
thrombolysis in myocardial infarction (SAVOR-TIMI) 53
study. Am Heart J. 2011;162:818–825. e6.
43. Standl E, Schnell O. DPP-4 inhibitors and risk of heart failure
EXAMINEd. Lancet. 2015;385:2022–2024.
44. Jackson N, Atar D, Borentain M, et al. Improving clinical
trials for cardiovascular diseases: a position paper from the
Cardiovascular Round Table of the European Society of
Cardiology. Eur Heart J. 2015. Jun 15. pii: ehv213. [Epub ahead
of print].
45. Hirshberg B, Katz A. Cardiovascular outcome studies with
novel antidiabetes agents: scientiﬁc and operational
considerations. Diabetes Care. 2013;36:S253–S258.
46. Bloomgarden Z, Grunberger G. Cardiovascular safety trials:
be careful what you wish for. J Diabetes. 2014;6:1–3.
47. European Medicines Agency. Guideline on clinical
investigation of medicinal products in the treatment of
diabetes mellitus [Internet]. [cited 2015 Nov 22]; Available
from: http://www.ema.europa.eu/docs/en_GB/document_
library/Scientiﬁc_guideline/2011/10/WC500115945.pdf.
48. Matthews DR. Cardiovascular trials and diabetes
treatments: a regulatory maze. Diabetes Vasc Dis Res.
2012;9:83–84.
49. Close K. A Complicated Case of the Heart – FDA Meets on Heart
Safety of Diabetes Drugs [Internet]. diaTribe 2015. 2015 [cited 2015
Nov 22] Available from: http://diatribe.org/complicated-case-
heart-fda-meets-heart-safety-diabetes-drugs.
50. Bethel MA, Holman R, Haffner SM, et al. Determining the
most appropriate components for a composite clinical trial
outcome. Am Heart J. 2008;156:633–640.
51. Yayan J. Emerging families of biomarkers for coronary artery
disease: inﬂammatory mediators. Vasc Health Risk Manag.
2013;9:435–456.
52. Barter PJ, Caulﬁeld M, Eriksson M, et al. Effects of torcetrapib
in patients at high risk for coronary events. N Engl J Med.
2007;357:2109–2122.
53. Caveney EJ, Cohen OJ. Diabetes biomarkers. J Diabetes Sci
Technol. 2011;5:192–197.
